Alnylam sues Pfizer, Moderna over patent used in mRNA COVID vaccines
Andrii Dodonov/iStock via Getty Images         


Alnylam Pharmaceuticals (NASDAQ:ALNY) has filed a patent infringement lawsuit against Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) arguing that the companies' COVID-19 mRNA vaccines infringe on a Moderna (MRNA) patent.
Alnylam (ALNY) said that the patent in question, 11,246,933, relates to biodegradable cationic lipids "that are foundational to the success of the mRNA COVID-19 vaccines."
In the complaint, Alnylam (ALNY) is seeking compensation from the two companies only and does not want to stop the sale and distribution of the vaccines.
Read why Seeking Alpha contributor Stephen Simpson argues that Alnylam (ALNY) is a buy.